Suppr超能文献

三联金属支架置入术治疗恶性肝门部胆管梗阻

Combined side-by-side and stent-in-stent method for triple metal stenting in patients with malignant hilar biliary obstruction.

机构信息

Department of Gastroenterology, Aichi Medical University, Aichi, Japan.

出版信息

Dig Endosc. 2019 Nov;31(6):698-705. doi: 10.1111/den.13448. Epub 2019 Jun 13.

Abstract

BACKGROUND AND AIM

Endoscopic placement of three branched self-expandable metallic stents (SEMS) for high-grade malignant hilar biliary obstruction (MHBO) is technically challenging. We examined the feasibility and efficacy of a novel stenting method combining side-by-side and stent-in-stent (SBSIS) placement for MHBO.

METHODS

Between January 2015 and December 2018, 27 consecutive patients with high-grade MHBO underwent SBSIS placement. We evaluated the technical success, functional success, recurrent biliary obstruction (RBO), adverse events other than RBO, and reintervention success rates associated with SBSIS placement.

RESULTS

Technical success rate was 85% (23/27). Insertion of the third SEMS failed in four patients, and median diameter of the common bile duct (CBD) was significantly smaller in patients in whom technical failure occurred (5 mm vs 8 mm; P = 0.004). Functional success was achieved in all patients in whom the procedure was a technical success. Rate of adverse events other than RBO was 15% (4/27). RBO rate was 43% (10/23), and median time to RBO was 157 days. Success rate of endoscopic reintervention for RBO was 89% (8/9).

CONCLUSION

SBSIS placement showed favorable results and is a promising option in patients with high-grade MHBO requiring triple metal stenting. However, it might be preferable to avoid SBSIS in patients with a narrow CBD. Clinical Trial Registry: UMIN000035721.

摘要

背景与目的

内镜下放置三个分支自膨式金属支架(SEMS)治疗高位恶性肝门胆管梗阻(MHBO)技术上具有挑战性。我们研究了一种新型支架置入方法(SBSIS)治疗高位 MHBO 的可行性和疗效。

方法

2015 年 1 月至 2018 年 12 月,连续 27 例高位 MHBO 患者接受 SBSIS 治疗。我们评估了 SBSIS 治疗的技术成功率、功能成功率、复发性胆道梗阻(RBO)、RBO 以外的不良事件以及再介入成功率。

结果

技术成功率为 85%(23/27)。4 例患者第三根 SEMS 无法置入,技术失败患者的胆总管(CBD)中位直径明显更小(5mm 比 8mm;P=0.004)。在技术成功的患者中,所有患者均获得功能成功。RBO 以外不良事件的发生率为 15%(4/27)。RBO 发生率为 43%(10/23),中位 RBO 发生时间为 157 天。RBO 的内镜再介入成功率为 89%(8/9)。

结论

SBSIS 置入术在需要三枚金属支架置入的高位 MHBO 患者中显示出良好的效果,是一种有前途的选择。然而,对于 CBD 狭窄的患者,可能最好避免使用 SBSIS。

临床试验注册号

UMIN000035721。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验